ArticleCell regeneration (London, England)2025
The validation of quality attributes in Primary Human Hepatocytes Standard.
Article in Cell regeneration (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver-bone model.Archives of toxicology · 2026Article
- Systematic comparison of temporal hepatotoxicant-induced gene network responses across 3 liver test systems.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Article
- Construction of liver organoid models by hepatobiliary differentiation from human induced pluripotent stem cells: state of the art, challenges and improving strategies.Stem cell research & therapy · 2026Review
- Reconstructing Liver Fibrosis: 3D Human Models, Microbiome Interfaces, and Therapeutic Innovation.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Primary human hepatocytes (PHH) are used as the FDA-recognized "gold standard" for liver-related studies in vitro. The world's first PHH group standard (T/CSCB 0008-2021, CSCB standard) was released by Chinese Society for Cell Biology in 2021. In order to justify this standard, six key quality attributes of ten different batches from commercial PHHs, including cell viability, cell morphology, cell markers, albumin secretion, drug metabolism function and bile secretion, were characterized using the designated test methods in the standard. The PHHs from various batches all exhibited typical hepatocytic morphology, high cell viability, and sufficient albumin secretion; whereas, tremendous variations in cell markers, drug metabolism functions, and bile secretion were unexpectedly detected across the board. Flow cytometric assessment of hepatocyte markers revealed the percentages of ALB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.